In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.
BARCELONA, Spain and COPENHAGEN, Denmark, February 17, 2021 / B3C newswire / — Almirall S.A. (BME: ALM), a global biopharmaceutical company and MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical therapies for autoimmune and chronic inflammatory conditions, announced today an agreement under which MC2 Therapeutics has granted Almirall exclusive European rights to commercialize Wynzora® Cream for treatment of plaque psoriasis. In exchange, MC2 Therapeutics is eligible to receive upfront to launch payments of EUR 15 million in addition to significant sales milestone payments and double-digit royalties on the European sales of Wynzora® Cream. Almirall and MC2 Therapeutics partner to make Wynzora® Cream a leading topical product for treatment of plaque psoriasis in Europe – a market, which currently is more than 25 million units in sales volume annually (2). The market represents a significant opportunity for Wynzora® Cream as the calcipotriene and betamethasone dipropionate segment accounts for approximately 35% of share of volume and annual sales of more than $300 million (2).
Read the full press release here